Medarex, Inc. today announced a collaborative research agreement with Mitsubishi Pharma Corporation, a subsidiary of Mitsubishi Chemical Holdings Corporation . The two companies expect to generate and evaluate fully human monoclonal antibodies against a Mitsubishi target for the potential treatment of autoimmune diseases. The companies plan to use Medarex's UltiMAb Human Antibody Development System(R) to generate antibodies for research and possible development.

Under the terms of the agreement, Medarex and Mitsubishi Pharma will share research responsibilities for any antibodies generated through the collaboration. Other terms of the agreement were not disclosed.

"We are very much pleased to work with Medarex," said Dr. Tohru Nakajima, Executive Officer/Division Manager of the Pharmaceutical Research Division for Mitsubishi Pharma. "We will gain access to excellent expertise that provides us with the potential advancement of novel therapeutics for autoimmune diseases."

"We are pleased to have this opportunity to partner with Mitsubishi Pharma Corporation and its research team and to work together to potentially discover new antibody therapeutics," said Irwin Lerner, Interim President and CEO of Medarex.


'"/>




Page: 1
Related medicine news :

1. Ramdoss Announces Introduction of RCH-II
2. Britain Announces Third Transfusion Related Mad Cow Case
3. Tibet Announces the Dalai Lama’s Tour of South Americ
4. Indian PM Announces Of Setting Up India Study Center At Tashkent
5. PowderMed Announces Needle-Less Flu Vaccine
6. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
7. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
8. Australian Government Announces Survey To Tackle Childhood Obesity
9. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
10. Apollo Announces Research on Indian Cardiac Epidemic
11. Government Announces Steps To Promote Ayurvedic Medicine